Skip to main content
NewslettersWatchlist

Pieris Pharmaceuticals Inc(PIRS-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low11.38
Day High11.74
Open:11.63
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
ACCESSWIRE
Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
ACCESSWIRE
Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring
ACCESSWIRE
Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study
ACCESSWIRE
Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference
ACCESSWIRE
Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference
ACCESSWIRE
Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference
ACCESSWIRE
Pieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Updates
ACCESSWIRE
Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep (PRS-060/AZD1402)
ACCESSWIRE
Pieris Pharmaceuticals to Host First Quarter 2023 Investor Call and Provide Corporate Update on May 10, 2023
ACCESSWIRE
Pieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa (PRS-343) At 2023 AACR Annual Meeting
ACCESSWIRE
Pieris Pharmaceuticals Reports Full-Year 2022 Financial Results and Business Updates
ACCESSWIRE
Pieris Pharmaceuticals to Host Year End 2022 Investor Call and Provide Corporate Update on March 29, 2023
ACCESSWIRE
Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule (Mabcalin SGN-BB228 (PRS-346)
ACCESSWIRE
Pieris Pharmaceuticals To Present at Evercore ISI Healthconx Conference
ACCESSWIRE
Pieris Pharmaceuticals to Present at Jefferies London Healthcare Conference
ACCESSWIRE
Pieris Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
ACCESSWIRE
Pieris Pharmaceuticals Announces Dosing of First Subject in Phase 1 Trial of Inhaled CTGF Inhibitor PRS-220
ACCESSWIRE
Pieris Pharmaceuticals To Host Third Quarter 2022 Investor Call and Provide Corporate Update on November 2, 2022
ACCESSWIRE
Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference
ACCESSWIRE
Pieris Pharmaceuticals Announces Presentation of Preclinical Data for Inhaled Jagged-1 Inhibitor PRS-400 at ERS
ACCESSWIRE
Pieris Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
ACCESSWIRE
Pieris Pharmaceuticals to Host Second Quarter 2022 Investor Call and Provide Corporate Update on August 4, 2022
AccessWire
Pieris Pharmaceuticals To Present at Jefferies Healthcare Conference
Business Wire
Chau Khuong Joins Catalio Capital Management as General Partner
AccessWire
Pieris Pharmaceuticals To Present at H.C. Wainwright Global Investment Conference
AccessWire
Pieris Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
AccessWire
Pieris Pharmaceuticals To Host First Quarter 2022 Investor Call and Provide Corporate Update on May 11, 2022
Motley Fool
3 Risky Stocks With Huge Potential Upside
Motley Fool
This Pharmaceutical Stock Could Be Your Lottery Ticket
Motley Fool
This Pharmaceutical Stock Could Bank Billions Soon
Motley Fool
3 Biotechs That Will Crush the Bear
Motley Fool
Up 1,000% in 5 Years? These Healthcare Stocks Could Pull It Off.

Profile

Pieris Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's drug technology consists of Anticalin(R) to treat cancer, severe asthma, anemia and other medical conditions. Pieris Pharmaceuticals, Inc. is based in Freising-Weihenstephan, Germany.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.